Table 1 -.

PR3-ANCA Reactivities with iHm5 and iPR3.

The WGET study* 148 PR3-ANCA–positive samples*
iHm5 positive	iPR3 positive
n = 144	n = 135
Comparison of reactivity in 135 samples positive for both antigens
iHm5 > iPR3	iHm5 = iPR3	iHm5 < iPR3
n = 108	n = 26	n = 1
80%	19%	1%
The RAVE trial 129 PR3-ANCA–positive samples**
iHm5 positive	iPR3 positive
n = 128	n = 126
Comparison of reactivity in 126 samples positive for both antigens
iHm5 > iPR3	iHm5 = iPR3	iHm5 < iPR3
n = 89	n = 34	n = 3
71%	27%	2%

Comparison of the net absorbance values of the PR3-ANCA reactivity with iHm5 and iPR3. In 71-80% of the samples, a higher PR3-ANCA recognition of iHm5 was documented. Additionally, in 19-27% of the patients, iHm5 and iPR3 were equally recognized. Very few patients displayed higher recognition of iPR3: 1 in the RAVE trial and 3 in the WGET. [When the confidence interval overlapped, the determinations were considered equal.

^*Positive for PR3-ANCA in at least one antigen-specific immunoassay (Finkielman et al. Am J Med. 2007)

^**Positive for PR3-ANCA in at least one antigen-specific immunoassay (Fussner et al. Arthritis Rheum 2016)].